EU Pharma Trial Data Rigged for Faster Approvals

Whispers from Brussels suggest a systemic issue within the EU's pharmaceutical regulatory framework. Multiple sources within EMA-affiliated contract research organizations (CROs) indicate a pattern of 'data smoothing' and selective reporting in clinical trial submissions. This isn't outright fabrication, but rather a subtle manipulation of trial endpoints and adverse event reporting to present a more favorable risk-benefit profile. The pressure to expedite approvals, particularly for blockbuster drugs, creates an environment where data integrity is compromised. This intelligence highlights a potential vulnerability in the EU's drug safety net, impacting patient health and public trust. The focus is on trials conducted across several member states, with particular scrutiny on submissions from large multinational pharmaceutical firms. The implications for ongoing post-market surveillance are significant if the initial data was flawed.